Free Trial

Aequus Pharmaceuticals (AQS) Insider Trading & Ownership

Aequus Pharmaceuticals logo
C$0.0050 -0.01 (-50.00%)
(As of 12/17/2024)

Aequus Pharmaceuticals (CVE:AQS) Insider Buying and Selling Activity

Current
Insider Ownership
Percentage
14.68%
Number Of
Insiders Buying
(Last 3 Years)
2
Amount Of
Insider Buying
(Last 3 Years)
C$26,540.00
Number Of
Insiders Selling
(Last 3 Years)
0
Get AQS Insider Trade Alerts

Want to know when executives and insiders are buying or selling Aequus Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

AQS Insider Buying and Selling by Quarter

Aequus Pharmaceuticals Insider and Congressional Trades History

Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/30/2022Doug JanzenDirectorBuy285,000C$0.04C$11,400.00
11/20/2022Doug JanzenDirectorBuy115,000C$0.03C$3,450.00
7/25/2022Marc LustigDirectorBuy64,000C$0.07C$4,480.00
7/21/2022Marc LustigDirectorBuy4,000C$0.07C$280.00
7/19/2022Doug JanzenDirectorBuy99,000C$0.07C$6,930.00
(Data available from 1/1/2013 forward)

AQS Insider Trading Activity - Frequently Asked Questions

The list of insiders at Aequus Pharmaceuticals includes Doug Janzen, and Marc Lustig. Learn more on insiders at AQS.

14.68% of Aequus Pharmaceuticals stock is owned by insiders. Learn more on AQS's insider holdings.

Aequus Pharmaceuticals Key Executives

  • Mr. Douglas Glen Janzen (Age 55)
    Chairman, CEO & President
    Compensation: $206.25k
  • Ms. Ann Fehr CGA (Age 55)
    CPA, CFO & Corporate Secretary
    Compensation: $136.13k
  • Mr. Grant Larsen
    Chief Commercial Officer


This page (CVE:AQS) was last updated on 12/22/2024 by MarketBeat.com Staff
From Our Partners